Study wrapper · #1228
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Editor's note
This is the strongest available synthesis on the amylin-plus-incretin combination, and it uses RoB 2 and GRADE rather than pooling uncritically. The head-to-head comparisons against both monotherapies are the load-bearing part: the additive effect is large and consistent across trials, while glycaemic outcomes were heterogeneous. Durability past the trial windows and long-term tolerability remain open, and the authors say so.
Plain-language abstract
This systematic review pooled seven randomized trials covering 8,069 people to compare CagriSema, a fixed-dose combination of cagrilintide and semaglutide, against placebo and against each component alone. Pooled weight loss with the combination was about 7.6 kg greater than semaglutide alone, 9.2 kg greater than cagrilintide alone, and 14.0 kg greater than placebo. Side effects were mostly gastrointestinal and injection-site reactions, with no signal of more serious adverse events.